Schwarz Pharma Reports Positive Results for Rotigotine Phase IIb Trials to Treat Restless Legs Syndrome
Aderis Pharmaceuticals partner, Schwarz Pharma, announces that the multinational Phase IIb trial with rotigotine has shown a statistically significant and clinically relevant reduction of RLS symptoms.
Hopkinton, MA - Jul 12, 2004 - Aderis Pharmaceuticals partner, Schwarz Pharma, reports positive Phase IIb results for rotigotine in a double blind, placebo controlled clinical trial of 310 patients with moderate to very severe Restless Legs Syndrome.
"At Aderis, we are excited about the progress of our product candidates and their potential ability to improve quality of life for millions of people. We are committed to helping patients and investors understand our progress as we achieve corporate and clinical milestones."
-Kenneth L. Rice, Jr.,
Chief Commercial Officer, Aderis Pharmaceuticals
back to top
